Outcome of Board Meeting held on 08 th October 2025, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs held a board meeting on 8 October 2025 that approved the final draft of a Share Purchase Agreement to acquire AMR Pharma India Private Limited, with Managing Director Nanjappan Aravind authorized to sign. The board also appointed two new Non-Executive Independent Directors — Ms. Ritu Tiwari and Ms. Nikita Sinha — for five-year terms starting 8 October 2025, and appointed Mr. T. Pavanasam as the new Chief Financial Officer. At the same meeting, Mr. Bangalore Venkatakrishnappa Ananth Kumar resigned as Whole-Time Director & CFO, and Mrs. Ananthkumar Shilpa resigned as Director.
Shareholders should view this as a significant restructuring: a planned acquisition combined with a leadership change at the CFO level may signal strategic expansion but also introduces execution risk. The new independent directors strengthen board oversight, while the resignations suggest a notable churn at the top that investors should monitor.